GENE ONLINE|News &
Opinion
Blog

2022-11-30| Trials & Approvals

Eisai Unveils Lecanemab Data Following Reports of Second Alzheimer’s Patient Death

by Reed Slater
Share To
Before the FDA’s upcoming approval decision for Eisai’s Alzheimer’s treatment, lecanemab, the company released Phase 3 study data from the confirmatory CLARITY AD trial. The release comes just days after reports of a second patient death in the trial, which Eisai addressed, saying both deaths resulted from substantial comorbidities and risk factors, not from lecanemab.

It's free! Log in now to read

LATEST
Junshi’s PD-1 Antibody Meets Endpoint In Phase 3 Lung Cancer Trial
2023-01-19
Moderna Welcomes Phase 3 Win For RSV Vaccine
2023-01-18
Moving Beyond COVID With mRNA Technology
2023-01-18
Rob Knight and Jing-Yuan Fu Elaborate On Microbiome Research Trends at the 7th Asia Microbiome Conference(AMC)
2023-01-17
CARsgen Taps Huadong to Commercialize Multiple Myeloma CAR-T in China
2023-01-17
Scientists Study Imaging Probes in First-Ever Amputated Human Limb Model
2023-01-16
EMA Plans to Issue Liver Failure Warning for Novartis’ Gene Therapy
2023-01-16
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!